Publications:54
Megan L Shaw, PhD
About Me
Language
English
Position
ADJUNCT ASSOCIATE PROFESSOR | Microbiology
Research Topics
Antivirals, Biodefense, Immune Antagonism, Infectious Disease, Influenza Virus, Nipah Virus, Viruses and Virology
Multi-Disciplinary Training Areas
Microbiology [MIC]
Education
B.Sc., University of Cape Town
B.Sc. (Med)Honors, University of Cape Town
Ph.D., University of Glasgow
Research
The Shaw laboratory is interested in the interactions that occur between RNA viruses and their hosts at the molecular level and how this knowledge may be used for understanding viral pathogenesis and for developing new antiviral drugs. The research involves basic molecular biology and virology techniques combined with RNAi, proteomics and high-throughput screening of small molecular weight compounds.
Our major focus is on identifying new antivirals for influenza virus as well as host proteins that are required by the virus and therefore may serve as novel drug targets. Another interest of the Shaw lab is the host antiviral response and specifically the mechanisms that viruses use to block this response. One virus of particular interest to us is Nipah virus, with is a highly pathogenic, emerging paramyxovirus. Nipah virus encodes multiple proteins that inhibit the antiviral response and our goal is to determine their mechanisms of action and their individual contributions to virus pathogenesis.
Publications
Selected Publications
- Small molecule inhibition of the mitochondrial lipid transfer protein STARD7 attenuates influenza viral replication. Shipra Sharma, Oyahida Khatun, Jihaan Adonis, Shaochen You, Kevin Hartenbower, Vedita Anand Singh, Namir Shaabani, Saikat De, Emi R. Matsuo, Rachel Y. Sattler, Jonathan A. Covel, Kris M. White, Laura Martin-Sancho, Malina A. Bakowski, Dylan J. Mendonsa, Ayush Mehta, Noura S. Yassir, Steven H. Olson, Naoko Matsunaga, Adolfo García-Sastre, Michael J. Bollong, Nisar A. Farhat, Megan L. Shaw, Sumit K. Chanda. PLoS pathogens
- Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants. S. Jaumdally, M. Tomasicchio, A. Pooran, A. Esmail, A. Kotze, S. Meier, L. Wilson, S. Oelofse, C. van der Merwe, A. Roomaney, M. Davids, T. Suliman, R. Joseph, T. Perumal, A. Scott, M. Shaw, W. Preiser, C. Williamson, A. Goga, E. Mayne, G. Gray, P. Moore, A. Sigal, J. Limberis, J. Metcalfe, K. Dheda. Nature Communications
- Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters. Yolandy Lemmer, Ros Chapman, Celia Abolnik, Tanja Smith, Georgia Schäfer, Tandile Hermanus, Ilse du Preez, Kruger Goosen, Kamogelo M. Sepotokele, Sophette Gers, Tasnim Suliman, Wolfgang Preiser, Megan L. Shaw, Robyn Roth, Alma Truyts, John Chipangura, Martin Magwaza, Osborn Mahanjana, Penny L. Moore, Martha M. O'Kennedy. Vaccine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Shaw has not yet completed reporting of industry relationships or has no industry relationships to report.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.